nach oben

Erschienen in:

05.09.2014 | Original Article

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

verfasst von: Mona M. El Temsahy, Eman D. H. El Kerdany, Maha M. Eissa, Thanaa I. Shalaby, Iman M. Talaat, Nermine M. F. H. Mogahed

Erschienen in: Journal of Parasitic Diseases | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Toxoplasmosis, a zoonotic parasitic disease, is a huge challenge for which there is no effective vaccine up till now. In this study, chitosan nanospheres encapsulated with Toxoplasma lysate vaccine was evaluated for its ability to protect mice against both acute and chronic toxoplasmosis models of infection. Results showed that chitosan nanospheres were equally effective to Freund’s incomplete adjuvant (FIA) in enhancing the efficacy of Toxoplasma lysate vaccine. The effectiveness was demonstrated by the delayed death of vaccinated mice following challenge either with virulent RH or avirulent Me49 strains, the significant decrease in parasite density in different organs, significant increase in the humoral and cellular immune response (IgG and IFN γ) with a marked reduction of pathological changes in the different organs. However chitosan nanospheres were superior to FIA due to their cost effective preparation and much less necrotic changes induced in the studied organs. The success of chitosan polymer as an alternative to commonly used adjuvants paves the way for the use of other newly developed polymers to be used in the field of vaccine development.

Abu-Madi AM, Al-Molawi N, Behnke MJ (2008) Seroprevalence and epidemiological correlates of Toxoplasma gondii infections among patients referred for hospital-based serological testing in Doha, Qatar. Parasites Vectors 1:3–9CrossRef

Angus CW, Klivington-Evans D, Dubey JP, Kovacs JA (2000) Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 181:317–324CrossRefPubMed

Araujo FG, Phillippe P, Teri L, Remington SJ (1992) Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agent Chemother 36(11):2454–2457CrossRef

Bakal PM, Veld N (1979) Response of white mice to inoculation of irradiated organisms of the Toxoplasma strain RH. Z Parasitenkd 59:211–217CrossRefPubMed

Black MW, Boothroyd JC (2000) Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev 64:607–623CrossRefPubMedPubMedCentral

Cambridge CD, Singh SR, Waffo AB, Fairley SJ, Dennis VA (2013) Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles. Int J Nanomed 8:1759–1771

Chan YH (2003) Biostatistics 102: quantitative data—parametric & non-parametric tests. Singap Med J 44(8):391–396

Chuang SC, Ko JC, Chen CP, Du JT, Yang CD (2013) Induction of long lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly(lactide-co-glycolide) microparticles. Parasites Vectors 6:34CrossRefPubMedPubMedCentral

Cong H, Zhang M, Xin Q, Wang Z, Li Y, Zhao Q et al (2013) DNA vaccine encoding SAG1/SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii. Parasites Vectors 6:63

Danesh-Bahreinni MA, Shokri J, Samiel A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohmmadi-Samani S (2011) Nanovaccine for leishmaniasis; preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/C mice. Int J Nanomed 6:835–842

Drury RAB, Wallington EA (1980) Carleton’s Histological technique, 5th edn. Oxford University Press, Oxford

Eissa MH, Antonious SN, Salama MMI, Fikry AA, Morsy TA (1990) Histopathological studies of acute, chronic and congenital infections of toxoplasmosis in mice. J Egypt Soc Parasitol 20:805–816PubMed

Eissa MM, El-Azzouni MZ, Mady RF, Fathy FM, Baddour NM (2012) Initial characterization of an autoclaved Toxoplasma vaccine in mice. Exp Parasitol 131(3):310–316CrossRefPubMed

Elsaid MMA, Vitor RWA, Frézard FJG, Martins MS (1999) Protection against Toxoplasmosis in mice immunized with different antigens of Toxoplasma gondii incorporated into liposomes. Mem Inst Oswaldo Cruz 94(4):485–490CrossRefPubMed

El-Temsahy M, El-Kerdany ED, Abou-Shamaa AM (2002) Study of the role of antioxidants in experimental toxoplasmosis. J Med Res Inst 23:59–69

Escajadillo A, Frenkel J (1991) Experimental toxoplasmosis and vaccine tests in Aotus monkeys. Am J Trop Med Hyg 44(4):382–389CrossRefPubMed

Filisetti D, Candolfi E (2004) Immune response to Toxoplasma gondii. Ann Ist Super Sanita 40(1):71–80PubMed

Gan Q, Wang T (2007) Chitosan nanoparticles as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B 59:24–34CrossRef

Garcia JL, Gennari SM, Navarro IT, Machado RZ, Sinhorini IL, Freire RL et al (2005) Partial protection against cysts formation in pigs vaccinated with crude rhoptery proteins of Toxoplasma gondii. Vet Parasitol 129:209–217CrossRefPubMed

Gatkowska J, Gasior A, Kur J, Dlugonska H (2008) Determination of the value of Toxoplasma recombinant ROP2 and ROP4 antigen in experimental toxoplasmosis. Exp Parasitol 118:266–270CrossRefPubMed

Handman E (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14:229–243CrossRefPubMedPubMedCentral

Hermes G, Ajika JW, Kelly KA, Mui E, Roberts F, Kasza K et al (2008) Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neural injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflamm 5:48CrossRef

Ismael AB, Dimier-Poisson I, Lebrun M, Dubremetz JF, Mevelec MN (2006) MIC1-3 knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice. J Infect Dis 194:1176–1183CrossRefPubMed

Johnson LL, Sayles PC (2002) Deficient humoral responses underlie susceptibility to Toxoplasma gondii in CD4-deficient mice. Infect Immunol 70(1):185–191CrossRef

Jongert E, Roberts CW, Gargano N, Förster-Waldi E, Petersen E (2009) Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz Rio J 104(2):252–266CrossRef

Kang H, Remington JS, Suzuki Y (2000) Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol 164(5):2629–2634CrossRefPubMed

Khan IA, Casciotti L (1999) IL-15 prolongs the duration of CD+8 T cell mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J Immunol 16:34503–34509

Kikumura A, Fang H, Mun HS, Uemura N, Makino M, Sayama Y et al (2010) Protective immunity against lethal anaphylactic reaction in Toxoplasma gondii-infected mice by DNA vaccination with T. gondii-derived heat shock protein 70 gene. Parasitol Int 59(2):105–111CrossRefPubMed

Kirkpatrick LA, Feeney BC (2013) A simple guide to IBM SPSS statistics for version 20.0, student ed. Wadsworth, Cengage Learning, Belmont, California, p 115

Krahenbuhl JL, Ruskin J, Remington JS (1972) The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii. J Immunol 108:425–431PubMed

Leslie E, Geoffrey J, James M (1991) Statistical analysis. In: Interpretation and uses of medical statistics, 4th edn. Oxford Scientific Publications, Oxford, pp 411–416

Mady RFM (2005) Efficacy of killed vaccine against experimental toxoplasmosis. MS Thesis, Faculty of Medicine, Alexandria University, Alexandria

Makino M, Uemura N, Moroda M, Kikumura A, Piao LX, Mohamed RM et al (2011) Innate immunity in DNA vaccine with Toxoplasma gondii-heat shock protein 70 gene that induces DC activation and Th1 polarization. Vaccine 29(10):1899–1905CrossRefPubMed

Martin V, Supanitsky A, Echeverria PC, Litwin S, Tanos T, De Roodt AR et al (2004) Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis. Clin Diagn Lab Immunol 11:704–710PubMedPubMedCentral

Martinez-Gomez F, Garcia-Gonzalez LF, Mondragon-Flores R, Bautista Garfias CR (2009) Protection against Toxoplasma gondii brain cyst formation in mice immunized with Toxoplasma gondii cytoskeleton proteins and Lactobacillus casei as adjuvant. Vet Parasitol 160:311–315CrossRefPubMed

Mcleod R, Frenkel JK, Estes RG, Mack DG, Eisenhauer PB, Gibori G (1988) Subcutaneous and intestinal vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to per oral and congenital Toxoplasma challenge. J Immunol 140(5):1632–1637PubMed

Meng M, He S, Zhao G, Bai Y, Zhou H, Cong H et al (2012) Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondii surface antigen 1(SAG1) and 14-3-3 protein in BALA/C mice. Parasites Vectors 5:273CrossRefPubMedPubMedCentral

Palatnik-de-Sousa CB (2008) Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26:1709–1724CrossRefPubMed

Pan Y, Li YJ, Zhao HY, Zheng JM, Xu H, Wei G et al (2002) Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharmacol 249(1–2):139–147CrossRef

Rabchevsky AG, Degos JD, Dreyfus PA (1999) Peripheral injections of Freund’s adjuvant in mice provoke leakage of serum proteins through the blood–brain barrier without inducing reactive gliosis. Brain Res 832:84–89CrossRefPubMed

Rabie MM, Fumie A, Mei C, Hye-Seong M, Kazumi N, Belal US et al (2003) Induction of protective immunity by DNA vaccination with Toxoplasma gondii HSP70, HSP30 and SAG1 genes. Vaccine 21:2852–2861CrossRef

Ravindran R, Bhowmick S, Das A, Ali N (2010) Comparison of BCG, MPL and Cationic liposomes adjuvant system in Leishmanial antigen vaccine formulations against murine leishmaniasis. BMC Microbiol 10:181CrossRefPubMedPubMedCentral

Saita K, Nagaoka S, Shirosaki T, Horikawa M, Matsuda S, Ihara H (2012) Preparation and characterization of dispersible chitosan particles with borate crosslinking and their antimicrobial and antifungal activity. Carbohydr Res 349:52–58CrossRefPubMed

Shams El-Din SA (2013) Evaluation of vaccination with Toxoplasma gondii trophozoite lysate and influenza virus vaccine against experimental murine toxoplasmosis. Acta Parasitol Glob 4(3):110–120

Sibley LD, Mordue DG, Su C, Robben DM, Howe DK (2002) Genetic approach to study virulence and pathogenesis in Toxoplasma gondii. Philos Trans R Soc Lond B 357:81–88CrossRef

Spencer JA, Smith BF, Guarino AJ, Blaghurn BL, Baker HJ (2004) The use of CPG as an adjuvant to Toxoplasma gondii vaccination. Parasitol Res 92:313–316CrossRefPubMed

Stoicov C, Whary M, Rogers AB, Lee FS, Klucevesk K, Li HC et al (2004) Coinfection modulates inflammatory responses and clinical outcome of Helicobacter felis and Toxoplasma gondii infections. J Immunol 173(5):3329–3336CrossRefPubMed

Tafaghodi M, Tabassi AS, Amiri N (2008) PLGA Nanospheres loaded with autoclaved Leishmania major (ALM) and CPG-ODN: preparation and in vitro characterization. Iran J Basic Med Sci 11(2):112–119

Tan F, Hu X, Luo FJ, Pan CW, Chen XG (2011) Induction of protective Th1immune responses in mice by vaccination with recombinant Toxoplasma gondii nucleoside triphosphate hydrolase-II. Vaccine 29:2742–2748CrossRefPubMed

Tappeh KH, Khorshidvand Z, Shahabi S, Mohammadzadeh H (2013) A novel adjuvant, mixture of alum and naltrexone, elicits humoral immune responses for excreted/secreted antigens of Toxoplasma gondii tachyzoites vaccine in balb/c murine Model. Turk Parazitol Derg 37(2):92–96CrossRef

Tenter AM, Heckeroth AR, Weiss LM (2000) Toxoplasma gondii: from animals to humans. Int J Parasitol 30:1217–1258CrossRefPubMedPubMedCentral

Thiptara A, Kongkaew W, Bilmad U, Bhumibhamon T, Anan S (2006) Toxoplasmosis in piglets. Ann NY Acad Sci 1081:336–338CrossRefPubMed

Tiyaboonchai W (2003) Chitosan nanoparticles: a promising system for drug delivery. Naresuan Univ J 11(3):51–66

Turner HJ (1983) Detection of soluble antigens of Toxoplasma gondii four-layer modification of an enzyme immunoassay. J Clin Microbiol 17(5):768–773

Wang HL, Li YQ, Yin LT, Meng XL, Guo M, Zhang JH (2013) Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis. PLoS One 8(8):e70884CrossRefPubMedPubMedCentral

Yan HK, Yuan ZG, Petersen E, Zhang X, Zhou DH, Liu Q et al (2011) Toxoplasma gondii: protective immunity against experimental toxoplasmosis induced by a DNA vaccine encoding the perforin-like protein 1. Exp Parasitol 128:38–43CrossRefPubMed

Yap SG, Kersten TS, Ferguson DJ, Howe D, Susuki Y, Sher A (1998) Partially protective vaccination permits the development of latency in a normally virulent strain of Toxoplasma gondii. Infect Immunol 66(9):4382–4388

Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Grenier JW (2007) Chitosan solution enhances both humoral and cell mediated immune responses to subcutaneous vaccination. Vaccine 25(11):2085–2094CrossRefPubMed

Zhang NZ, Huang SY, Zhou DH, Chen J, Xu Y, Tian WP et al (2013) Protective immunity against Toxoplasma gondii induced by DNA immunization with the gene encoding a novel vaccine candidate: calcium-dependent protein kinase 3. BMC Infect Dis 13(1):512CrossRefPubMedPubMedCentral

Zhao G, Zhou A, Lu G, Meng M, Sun M, Bai Y et al (2013a) Identification and characterization of T. gondii aspartic protease as a novel vaccine. Parasites Vectors 14(6):175CrossRef

Zhao G, Zhou A, Lu G, Meng M, Min S, Bai Y (2013b) Toxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmosis. BMC Infect Dis 13:207CrossRefPubMedPubMedCentral

Titel: The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice
verfasst von: Mona M. El Temsahy
Eman D. H. El Kerdany
Maha M. Eissa
Thanaa I. Shalaby
Iman M. Talaat
Nermine M. F. H. Mogahed
Publikationsdatum: 05.09.2014
Verlag: Springer India
Erschienen in: Journal of Parasitic Diseases / Ausgabe 3/2016
Print ISSN: 0971-7196
Elektronische ISSN: 0975-0703
DOI: https://doi.org/10.1007/s12639-014-0546-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Fenvalerate resistance status in Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) from Punjab, India

Changes of haematological indices of grass carp, Ceteopharyngodon idella exposed to monogenean parasites, Gyrodactylus spp. and Dactylogyrus spp.

Diagnostic and prognostic value of cell free circulating Schistosoma mansoni DNA: an experimental study

Two Nerocila species parasitizing Pomadasys maculatus from Nagapattinam, Southeast coast of India

In vitro studies on medicinal plants used against bacterial diabetic foot ulcer (BDFU) and urinary tract infected (UTI) causing pathogens

Prevalence of intestinal parasites in Isfahan city, central Iran, 2014

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Adjuvante Brustkrebstherapie: Doppelt hält besser

Delir kann Demenz begünstigen

Update Innere Medizin